Market Place
Sourcing Support
Clarametyx Bio Announces Investment by Kineticos Accelerator Fund
28 Jan 2025 //
BUSINESSWIRE
Clarametyx Wins CARB-X Deal To Advance Anti-Biofilm Vaccine
07 Jan 2025 //
BUSINESSWIRE
Clarametyx Progresses Study On CMTX-101 Antibody Therapy
17 Oct 2024 //
BUSINESSWIRE
Clarametyx Bio: Renowned Advisors Added To Strategic, Scientific Boards
28 May 2024 //
BUSINESSWIRE
Clarametyx Biosciences Expands Team Expertise to Accelerate Pipeline Momentum
22 Apr 2024 //
BUSINESSWIRE
Clarametyx Biosciences Announces $33M Series A Financing
05 Jan 2024 //
BUSINESSWIRE
Clarametyx Announces Positive Early Phase 1 Safety Findings on CMTX-101
01 Jun 2023 //
BUSINESSWIRE
Clarametyx Biosciences Announces Changes to Its Scientific Advisory Board
30 May 2023 //
BUSINESSWIRE
Clarametyx launches Phase Ia bacterial pneumonia antibody trial
01 Dec 2022 //
CLINICALTRIALSARENA
Clarametyx Initiates Phase 1 Study of Immune-enabling Antibody Therapy CMTX-101
30 Nov 2022 //
BUSINESSWIRE
Clarametyx Announces FDA Acceptance of IND Application for PI Study of ICMTX-101
05 Oct 2022 //
BUSINESSWIRE
CARB-X Awards Clarametyx Biosciences $3.89M in Additional Option Funding
04 Apr 2022 //
BUSINESSWIRE
Data Published in eBioMedicine Validates Novel Scientific Approach That Disarms
07 Jul 2020 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.